表紙
市場調查報告書

焦點市場分析:骨關節炎

Market Spotlight: Osteoarthritis and Osteoarthritis Pain

出版商 Datamonitor Healthcare 商品編碼 573559
出版日期 內容資訊 英文 49 Pages
商品交期: 最快1-2個工作天內
價格
焦點市場分析:骨關節炎 Market Spotlight: Osteoarthritis and Osteoarthritis Pain
出版日期: 2020年08月21日內容資訊: 英文 49 Pages
簡介

根據Datamonitor Healthcare的數據,全球30歲以上的成人中,骨關節炎(膝或髖關節)的患病人數2017年推算為3億890萬人,預計2026年之前將增加到3億5,840萬人。全球骨關節炎的盛行率推算為8.2%。 骨關節炎領域批准的藥物集中於多種靶標。這些治療方法大多數是通過口服途徑進行的,其餘的則是局部,關節內和經皮的治療。

本報告提供骨關節炎的治療藥市場相關分析,提供疾病概要和患者數的轉變·預測,目前的主要治療方法及臨床實驗·認證情形,骨關節炎治療藥市場趨勢預測 (今後10年份),資本交易的動向,現在正在開發臨床實驗的進展等調查。

概要

要點

疾病的背景

治療

  • 非藥物治療
  • 藥物治療
  • 手術

流行病學

已上市藥物

開發平台藥物

近幾年的動向·分析師的見解:骨關節炎·變形性關節痛

近未來的動向

主要的法規動向

成功概率

授權·資產收購交易

母專利

商機

臨床試驗環境

  • 贊助商:各狀態
  • 贊助商:不同階段
  • 近幾年的活動

文獻

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DMKC0179226

This Market Spotlight report covers the Osteoarthritis and Osteoarthritis Pain market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways

Datamonitor Healthcare estimates that in 2019, there were 320.7 million prevalent cases of osteoarthritis (knee or hip) in adults aged 30 years and older worldwide, and forecasts that number to increase to 367.7 million prevalent cases by 2028.

The global prevalence of osteoarthritis is estimated to be 8.2%. The approved drugs in the osteoarthritis space focus on a wide variety of targets. The majority of these therapies are administered via the oral route, with the remainder being topical, intraarticular, and transdermal formulations.

The majority of industry-sponsored drugs in active clinical development for osteoarthritis are in Phase II, with only one drug in the NDA/BLA phase.

Therapies in development for osteoarthritis focus on a wide variety of targets. The largest proportion of pipeline drugs are administered via the intraarticular route.

High-impact upcoming events for drugs in the osteoarthritis space comprise topline Phase II and Phase III trial results, an expected PDUFA date for a BLA, an anticipated FDA advisory panel meeting, an expected decentralized approval in the EU, and an expected CHMP opinion.

The overall likelihood of approval of a Phase I osteoarthritis and osteoarthritis pain asset is 12.3%, and the average probability a drug advances from Phase III is 54.5%. Drugs, on average, take 12.7 years from Phase I to approval in the osteoarthritis and osteoarthritis pain space, as well as in the overall rheumatology (non autoimmune) space.

The distribution of clinical trials across Phase I-IV indicates that the majority of trials for osteoarthritis have been in the early and mid-phases of development, with 58% of trials in Phase I-II, and 42% in Phase III-IV.

The US has a substantial lead in the number of osteoarthritis clinical trials globally. The UK leads the major European markets, while South Korea has the top spot in Asia.

Clinical trial activity in the osteoarthritis space is dominated by completed trials. Pfizer has the highest number of completed clinical trials for osteoarthritis, with 124 trials.

Pfizer leads industry sponsors with the highest overall number of clinical trials for osteoarthritis

TABLE OF CONTENTS

CONTENTS

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

TREATMENT

  • Non-pharmacological treatment
  • Pharmacological treatment
  • Surgery

EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

  • ATB-346 for Osteoarthritis and Osteoarthritis Pain (June 1, 2020)
  • GLPG1972 for Osteoarthritis and Osteoarthritis Pain (July 14, 2019)
  • Multiple Drugs for Osteoarthritis and Osteoarthritis Pain (June 25, 2019)
  • Tanezumab for Osteoarthritis and Osteoarthritis Pain (April 18, 2019)
  • Tanezumab for Osteoarthritis and Osteoarthritis Pain (January 29, 2019)

KEY UPCOMING EVENTS

KEY REGULATORY EVENTS

  • Virpax And MedPharm Advance Diclofenac Spray
  • Surprise! Pfizer And Lilly File Tanezumab For Pain With FDA Despite Safety Questions
  • FDA Misses Zilretta Goal Date, Flexion Says

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

  • $5bn Galapagos Deal Won't Be Last For Gilead, Says O'Day

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase
  • Recent events

BIBLIOGRAPHY

  • Prescription information

APPENDIX

LIST OF FIGURES

  • Figure 1: Trends in prevalent cases of osteoarthritis (knee or hip), 2019-28
  • Figure 2: Overview of pipeline drugs for osteoarthritis in the US
  • Figure 3: Pipeline drugs for osteoarthritis, by company
  • Figure 4: Pipeline drugs for osteoarthritis, by drug type
  • Figure 5: Pipeline drugs for osteoarthritis, by classification
  • Figure 6: ATB-346 for Osteoarthritis and Osteoarthritis Pain (June 1, 2020): Phase IIb - Dose-Ranging
  • Figure 7: Tanezumab for Osteoarthritis and Osteoarthritis Pain (April 18, 2019): Phase III - OA Safety Study (vs. NSAIDs)
  • Figure 8: Tanezumab for Osteoarthritis and Osteoarthritis Pain (January 29, 2019): Phase III - OA of Hip or Knee (6 Months EU Study)
  • Figure 9: Key upcoming events in osteoarthritis
  • Figure 10: Probability of success in the osteoarthritis pipeline
  • Figure 11: Clinical trials in osteoarthritis
  • Figure 12: Top 10 drugs for clinical trials in osteoarthritis
  • Figure 13: Top 10 companies for clinical trials in osteoarthritis
  • Figure 14: Trial locations in osteoarthritis
  • Figure 15: Osteoarthritis trials status
  • Figure 16: Osteoarthritis trials sponsors, by phase

LIST OF TABLES

  • Table 1: Prevalent cases of osteoarthritis (knee or hip), 2019-28
  • Table 2: Marketed drugs for osteoarthritis
  • Table 3: Pipeline drugs for osteoarthritis in the US
  • Table 4: ATB-346 for Osteoarthritis and Osteoarthritis Pain (June 1, 2020)
  • Table 5: GLPG1972 for Osteoarthritis and Osteoarthritis Pain (July 14, 2019)
  • Table 6: Multiple Drugs for Osteoarthritis and Osteoarthritis Pain (June 25, 2019)
  • Table 7: Tanezumab for Osteoarthritis and Osteoarthritis Pain (April 18, 2019)
  • Table 8: Tanezumab for Osteoarthritis and Osteoarthritis Pain (January 29, 2019)
  • Table 9: Historical global sales, by drug ($m), 2015-19
  • Table 10: Forecasted global sales, by drug ($m), 2020-24